The Center for Translational Pathology (CTP) will provide investigators with high quality, state of the art, and cost-effective tissue-based and clinical laboratory assays, biospecimens, consultative pathology services, multiparametric imaging, mass spectrometry, molecular pathology, mouse models and advanced cellular therapeutics for basic, translational, and clinical research. Originally established in 2007 as the Translational Research Program (TRP) within the Department of Pathology & Laboratory Medicine at Weill Cornell Medicine, the TRP has since grown and expanded to include numerous core facilities within the Department of Pathology & Laboratory Medicine. This new center will be a pillar for the Meyer Cancer Center and its designation as an NCI Comprehensive Cancer Center.
The former TRP, recently named the Center for Translational Pathology, has undergone a transformation over the last two years and currently offers comprehensive translational pathology services (e.g. tissue processing, special staining, nucleic acid extraction and processing, tissue microarray construction, archive and biobank specimen selection and retrieval, expert pathologist review), biomarker and experimental therapeutics testing and development (e.g. immunohistochemistry, immunofluorescence, in situ hybridization, flow cytometry, advanced cell therapy, patient-derived organoids and xenografts), and advanced visuospatial analysis and imaging techniques (e.g. multiparametric in situ imaging, digital slide scanning, automated image analysis) and large array of molecular tests for basic and translational determinations. The CTP is supported by the Department of Pathology & Laboratory Medicine that has made significant investments in new technologies, including the purchase of a Vectra® Polaris™ Automated Quantitative Pathology Imaging System, a CO-Detection by indEXing (CODEX) system, and a GeoMx® Digital Spatial Profiler from NanoString Technologies. In addition, the CTP’s Laboratory for Advanced Cellular Engineering (LACE) offers researchers cutting edge cGMP support to generate experimental cell-based therapeutic products. The department investment in patient-derived organoids, patient-derived-tumor-xenografts (PDTX), and ex vivo culture of tissues is also critical for advancement of personalized medicine and drug discovery. All of these services are provided on site and at similar cost to other New York City cancer centers. In 2019, more than 120 WCM investigators utilized the CTP (then the ‘TRP’) services. In summary, the CTP advances and supports the research of faculty and basic scientists through high quality tissue resources and cutting edge imaging and therapeutic technologies by providing an avenue for tissue research.
Led by Jorge Moscat, Ph.D., the CTP is a critical component and facilitator of the high-quality research performed in the department. CTP staff log projects into a database, track requests, monitor research integrity, and list resulting publications. We work closely with the Clinical Trials Office to process tissue samples for biospecimen studies.
The CTP understands how to catalyze clinical solutions quickly, with the highest quality and the best value. We believe the true application of translational research can be achieved by integrating research strategy, clinical collaboration, training, and education. Through the enthusiasm and efforts of our team and our collaborators, our goal is to improve the care and quality of life of all patients.
For inquiries and questions about the CTP, please contact: